#Biomanufacturing of Cds quantum dots A team of Lehigh University engineers have demonstrated a bacterial method for the low-cost, environmentally friendly synthesis of aqueous soluble quantum dot (QD) nanocrystals at room temperature.
This biosynthetic approach provides a viable pathway to realize the promise of green biomanufacturing of these materials.
the biomanufacturing technique cuts that cost to about $1-$10 per gram. The substantial reduction in cost potentially enables large-scale production of QDS viable for use in commercial applications."
harnessing nature to create functional inorganic materials will provide a pathway to a future environmentally friendly biomanufacturing based economy.
Earlier this month, MIT spinout Microchips Biotech partnered with a pharmaceutical giant to commercialize its wirelessly controlled, implantable,
Invented by Microchips Biotech cofounders Michael Cima, the David H. Koch Professor of Engineering, and Robert Langer, the David H. Koch Institute Professor, the microchips consist of hundreds of pinhead-sized reservoirs,
and osteoporosis. Michael Cima (left) and Robert Langer Now Microchips Biotech will begin co-developing microchips with Teva Pharmaceutical, the worlds largest producer of generic drugs,
Apart from providing convenience, Microchips Biotech says these microchips could also improve medication-prescription adherence a surprisingly costly issue in the United states. A 2012 report published in the Annals of Internal medicine estimated that Americans who dont stick to prescriptions rack up $100 billion
Microchips Biotech will continue work on its flagship product, a birth-control microchip, backed by the Bill and Melinda Gates Foundation,
Cima, who now serves on the Microchips Biotech board of directors with Langer sees this hormone-releasing microchip as one of the first implantable artificial organs because it acts as a gland.
A version of Microchip Biotech's implantable, wirelessly controlled microchip. When an electrical current is delivered to one of the chip's tiny reservoirs,
For years, the technology underwent rigorous research and development at Microchips Biotech. But in 2011, Langer and Cima,
MEMS innovations Microchips Biotech made several innovations in the microelectromechanical systems (MEMS) manufacturing process to ensure the microchips could be commercialized.
To do so, Microchips Biotech modified a cold-welding tongue and groove process. This meant depositing a soft,
which was published in Frontiers in Bioengineering and Biotechnology("Lauric acid production in a glycogen-less strain of Synechococcus sp.
including terpenoids-precursors to a range of commercial chemicals-and bioproducts, such as rubber, detergents, and polymers."
Aurasense, Inc.,a biotechnology company that licensed the Nanoflare technology from Northwestern University, and EMD-Millipore, another biotech company, have commercialized Nanoflares.
There are now more than 1, 700 commercial forms of Nanoflares sold under the Smartflare? name in more than 230 countries.
MIT is negotiating an exclusive license agreement with Lyndra, an early-stage biotechnology company developing novel oral drug-delivery systems, for this and other related technologies.
presented in the journal Biosensors & Bioelectronics, will improve treatments for neurologial disorders which currently rely on traditional electrical stimulation.
the biosensor could be placed in one part of the body, and trigger release of neurotransmitters at distant locations.
and Agneta Richter-Dahlfors in Biosensors & Bioelectronics. Published online April 22 2015 doi: 10.1016/j. bios. 2015.04. 058abstractan organic electronic biomimetic neuron enables auto-regulated neuromodulationcurrent therapies for neurological disorders are based on traditional medication and electric stimulation.
is achieved by connecting enzyme-based amperometric biosensors and organic electronic ion pumps. Selective biosensors transduce chemical signals into an electric current,
which regulates electrophoretic delivery of chemical substances without necessitating liquid flow. Biosensors detected neurotransmitters in physiologically relevant ranges of 50 M
showing linear response above 20 m with approx. 0. 1 na/M slope. When exceeding defined threshold concentrations, biosensor output signals, connected via custom hardware/software,
activated local or distant neurotransmitter delivery from the organic electronic ion pump. Changes of 20 M glutamate or acetylcholine triggered diffusive delivery of acetylcholine,
and uses biotechnology to convert viruses into therapeutic agents, effectively allowing them to go on seek
IPIC to Commercialize OCT Biosensor Raman Imager Speeds Cancer Detectio e
#Continuously Disinfecting Light Fixtures Commercialized Designed to continuously disinfect the air and surfaces in hospitals,
The british biotech company Oxitec has been developing a unique form of pest control for over a decade.
It was funded by Asthma UK, the Cardiff Partnership Fund, Marie Curie Initial Training Network, the Biotechnology and Biological sciences Research Council and the US National institutes of health t
Amgen, is to get approval from the FDA and the European Medicines Agency. The drug is administered once every two weeks for up to 18 months
By connecting enzyme-based biosensors to organic electronic ion pumps, Richter-Dahlfors and her team have managed now to create an artificial neuron that can mimic this function
the biosensor could be placed in one part of the body, and trigger release of neurotransmitters at distant locations.""
The results of lab trials have been published in the journal Biosensors and Bioelectronics. We're really looking forward to seeing where this research goes.
"The ability to deliver molecules into adherent cells without disrupting differentiation is needed for biotechnology researchers to advance both fundamental knowledge and the state-of-the-art in stem cell research,
From 1994 to 2004 the medical device biotechnology and pharmaceutical industries had annual growth rates greater than 6 percent per year with biotechnology demonstrating the largest increases.
The approach opens up new possibilities for the study of biomedical processes as well as for applications in biotechnology, chemistry, and pharmacy."
This is a fundamentally new approach for biology, biotechnology, and medicine,"says Schiller. With the help of chemical reactions that were previously impossible in the cell,
Schilller was awarded the research prize"Next Generation of Biotechnological Methods--Biotechnology 2020+"from the Federal Ministry of Education
This technology was licensed by the Biopancreate a wholly-owned subsidiary of Cortendo AB a biopharmaceutical company incorporated in Sweden
Strategies for converting fluorescent proteins into active biosensors of intracellular biochemistry are few in number and technically challenging comments Campbell.
and taking advantage of the fact that green and red fluorescence are mutually exclusive Ding was able to construct a wide variety of biosensors that underwent dramatic changes in fluorescence in response to biochemical processes of interest.
and engineering them to be biosensors that change their color in response to specific biological events Campbell has provided a tool for researchers to immediately pinpoint a major change at the cellular level minimizing the need for extensive biosensor optimization and providing
a versatile new approach to building the next generation of biosensors. This allows for a wide scope of applications notes Campbell.
an urban research and business park specializing in biotechnology, materials science and information technology. Wake Forest Baptist clinical, research and educational programs are ranked annually among the best in the country by U s. News & World Report u
Since the advent of biotechnology, researchers have modified bacteria to produce therapeutic drugs or antibiotics. In this novel study, they have actually become a diagnostic tool.
Professor Thomas is working on a delivery technology with Dendright Pty Ltd (a Uniquest start-up company) in collaboration Janssen Biotech Inc,
delivering enough energy to run a paper-based biosensor with nothing more than a drop of bacteria-containing liquid."
"While paper-based biosensors have shown promise in this area, the existing technology must be paired with hand-held devices for analysis. Choi says he envisions a self-powered system in
which a paper-based battery would create enough energy--we're talking microwatts--to run the biosensor.
'The research was supported by Cancer Research UK, the Wellcome Trust and the Biotechnology and Biological sciences Research Council UK K
#Biomanufacturing of Cds quantum dots A team of Lehigh University engineers have demonstrated a bacterial method for the low-cost, environmentally friendly synthesis of aqueous soluble quantum dot (QD) nanocrystals at room temperature.
This biosynthetic approach provides a viable pathway to realize the promise of green biomanufacturing of these materials.
the biomanufacturing technique cuts that cost to about $1-$10 per gram. The substantial reduction in cost potentially enables large-scale production of QDS viable for use in commercial applications."
harnessing nature to create functional inorganic materials will provide a pathway to a future environmentally friendly biomanufacturing based economy.
presented in the journal Biosensors & Bioelectronics, will improve treatments for neurologial disorders which currently rely on traditional electrical stimulation.
the biosensor could be placed in one part of the body, and trigger release of neurotransmitters at distant locations.
and biotechnology can join forces
#Fundamental beliefs about atherosclerosis overturned"The leading cause of death worldwide is complications of atherosclerosis,
A new trial will commence shortly using the Celgene CC-115 DNA-PKCS inhibitor. This new trial will be for patients advancing on standard of care therapies,
#Novel glycoengineering technology gives qualitative leap for biologics drug research Researchers from the University of Copenhagen have discovered a way of improving biotech drugs.
Nature Biotechnology. If glycoprotein-based pharmaceuticals are to produce the desired effect, the protein must be provided with a special sugar structure for enhanced therapeutic effect and duration.
and Australian chemists have figured out how to unboil egg whites an innovation that could dramatically reduce costs for cancer treatments, food production and other segments of the $160 billion global biotechnology industry,
Independently, the biotechnology company Prothena Corporation plc also discovered complementary data regarding MCAM, which led to an ongoing collaboration between the CRCHUM and Prothena.
who is also director of the NSF-NASA Center for Chemical Evolution and associate director of the Parker H. Petit Institute of Bioengineering and Bioscience,
The trial was funded by the manufacturer of T-VEC, Amgen, and is published in the Journal of Clinical Oncology.
Chesney and his team, working with the pharmaceutical company Amgen, are taking the success of their trials a step further combining T-VEC with the immune checkpoint inhibitor ipilimumab into a treatment regimen.
She has founded a service-based company called Lynx Biosciences based on these findings, and the company was recently a finalist in the 2015 Wisconsin Governor Business plan Contest.
for context, only 108 mammals are listed in the National Center for Biotechnology Information database. ntil recently,
To explain simply, it extracts power from bacteria the process delivers enough energy to run a paper-based biosensor with nothing more than a drop of bacteria-containing liquid.
which a paper-based battery would create enough energy to run the biosensor. Such sensors do not require a lot of power few microwatts would be enough.
These challenges have now been met with a new technique developed by researchers at the Energy Biosciences Institute (EBI
is likely to pave the way for the development of a wide range of new biotechnologies.
The research was supported by Cancer Research UK, the Wellcome Trust and the Biotechnology and Biological sciences Research Council UK e
UW-Madison has opened a genome editing facility in its Biotechnology Center. e want the whole campus to utilize this technology,
a private British biopharmaceutical company focused on the development of therapies for retinal dystrophies. e are leading the way in the development of an effective gene therapy treatment for choroideremia,
#TSRI and Biotech Partners Find New Antibody Weapons against Marburg virus A new study led by scientists at The Scripps Research Institute (TSRI) identifies new immune molecules that protect against deadly Marburg virus, a relative
and neutralize Marburg virushich has a mortality rate of up to 90%ere developed through an academic-industrial partnership including TSRI, Integrated Biotherapeutics, Mapp Biopharmaceutical and Emergent biosolutions.
Other antibodies in the study were identified independently at Mapp Biopharmaceutical and Integrated Biotherapeutics which collaborated with TSRI for molecular analysis. Some of the new antibodies target a new site on Marburg virus not seen before winglike feature attached to the base of the virus. Antibodies against this newly discovered site protected 90 to 100%of infected animal models from lethal infection.
or biosensors, in bacteria that are placed then in the gut, this paper stands out from the crowd by first engineering a member of the Bacteroides genus,
Based on these preclinical data, the HIV-1 version of this vaccine regimen is now being evaluated in an ongoing international clinical study sponsored by Crucell Holland BV
#Graphene-Based Biosensor Could Detect Cancer within Minutes One of the main reasons why treating most cancers is such a difficult task is our inability to detect its presence before it becomes widespread.
researchers at Trinity college Dublin are currently developing a highly-efficient biosensor that could pick up even the slightest presence of cancer within the body in mere minutes.
Professor Katsuhiko Shirahige (Institute of Molecular and Cellular Biosciences) and Ph d student Toyonori Sakata (Graduate school of Agricultural and Life sciences), isolated from cells
MIT is negotiating an exclusive license agreement with Lyndra, an early-stage biotechnology company developing novel oral drug-delivery systems,
according to a study published today (June 15) in Nature Biotechnology. his is an effective new system for extremely precise control of gene editing via light, Paul Knoepfler, a stem cell biologist at the University of California, Davis,
hotoactivatable CRISPR-Cas9 for optogenetic genome editing, Nature Biotechnology, doi: 10.1038/nbt. 3245,2015 d
#Tasty Visuals To help those with visual impairments make out the shape and movement of objects, a company has developed a device that takes visual information
#After Celgene Deal, Juno Revs Armored CAR For Ovarian Cancer Trial Juno Therapeutics has built remarkable momentumncluding last week much-dissected $1 billion deal with Celgenepon
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011